Magnesium Sulfate Versus Dexmedetomidine on Anesthesia Awakening.
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Magnesium sulfate (MS) and dexmedetomidine have already demonstrated the ability to reduce
intra and postoperative consumption of anesthetics and analgesics, among others advantages,
such as blood pressure control and intraoperative bleeding. The MS has also been shown to be
useful in pre-eclampsia and eclampsia control, pulmonary hypertension, asthma, cardiac
arrhythmias and pheochromocytoma). Despite these advantages in the use of these important
adjuncts, there is a concern about the quality and awakening time of the patients who use
them. The purpose of this trial is to compare the time and quality of awakening in patients
submitted to general anesthesia and receiving MS or dexmedetomidine as adjuncts in the
intraoperative analgesia.
The main objective of this trial is to compare the quality and the awakening time in patients
receiving MS or dexmedetomidine. The secondary objective is the comparison of postoperative
analgesia in the postoperative hospitalization period. Hypothesis: Our hypothesis is that
patients present a faster awakening when receive MS as an analgesic adjunct, when compared to
patients who receive dexmedetomidine. Drawing: this is a prospective, controlled, covert
trial with random distribution for noninferiority trialing.